Cook Jennifer E.'s most recent trade in BridgeBio Pharma Inc was a trade of 112,422 Common Stock done at an average price of $29 . Disclosure was reported to the exchange on July 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.00 per share. | 09 Jul 2026 | 112,422 | 139,805 (0%) | 0% | 29 | 3,260,238 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 09 Jul 2026 | 112,422 | 8,383 (0%) | 0% | 90 | 10,117,980 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2026 | 112,422 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 84.00 per share. | 09 Jul 2026 | 36,167 | 120,805 (0%) | 0% | 84 | 3,038,028 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 09 Jul 2026 | 19,000 | 27,383 (0%) | 0% | 8.5 | 160,550 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2026 | 19,000 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2026 | 17,167 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.75 per share. | 09 Jul 2026 | 17,167 | 156,972 (0%) | 0% | 16.7 | 287,547 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 22 Jun 2026 | 37,167 | 8,383 (0%) | 0% | 70 | 2,601,690 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 20,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 22 Jun 2026 | 20,000 | 28,383 (0%) | 0% | 8.5 | 169,000 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2026 | 17,167 | 17,167 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.75 per share. | 22 Jun 2026 | 17,167 | 45,550 (0%) | 0% | 16.7 | 287,547 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2026 | 5,277 | 5,277 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2026 | 3,990 | 10,579 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 68.57 per share. | 22 Jun 2026 | 2,196 | 8,383 (0%) | 0% | 68.6 | 150,580 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 15 Jun 2026 | 88,737 | 8,092 (0%) | 0% | 66.6 | 5,911,242 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 15 Jun 2026 | 65,921 | 79,662 (0%) | 0% | 8.4 | 557,032 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 65,921 | 39,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.75 per share. | 15 Jun 2026 | 17,167 | 96,829 (0%) | 0% | 16.7 | 287,547 | Common Stock |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 17,167 | 34,334 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 67.14 per share. | 15 Jun 2026 | 1,503 | 6,589 (0%) | 0% | 67.1 | 100,915 | Common Stock |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 19,226 | 19,226 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 6,408 | 32,483 (0%) | 0% | 0 | Common Stock | |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 3,507 | 12,642 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.25 per share. | 07 Aug 2025 | 1,805 | 10,837 (0%) | 0% | 111.2 | 200,805 | Ordinary Shares |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 13,741 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 18,111 | 18,111 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 6,037 | 26,075 (0%) | 0% | 0 | Common Stock | |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 3,731 | 10,619 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.35 per share. | 02 Aug 2024 | 1,484 | 9,135 (0%) | 0% | 111.3 | 165,243 | Ordinary Shares |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 21.73 per share. | 06 Jun 2024 | 1,458 | 20,038 (0%) | 0% | 21.7 | 31,682 | Common Stock |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,901 | 17,901 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 5,967 | 21,496 (0%) | 0% | 0 | Common Stock | |
| Jazz Pharma PLC | Cook Jennifer E. | Director | Sale of securities on an exchange or to another person at price $ 119.27 per share. | 04 Dec 2023 | 417 | 6,888 (0%) | 0% | 119.3 | 49,736 | Ordinary Shares |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 8,546 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Jennifer E. Cook | Director | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 11 Aug 2023 | 1,241 | 7,305 (0%) | 0% | 138.2 | 171,454 | Ordinary Shares |
| BridgeBio Pharma Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 12,649 | 12,649 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | Jennifer E. Cook | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,216 | 15,529 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Jennifer Cook E. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 3,576 | 7,152 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Jennifer Cook E. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 3,576 | 0 | - | - | Restricted Stock Units |